Nail Toxicities with FGFR Inhibitors — A JDD Systematic Review Worth Reading
Have you read this article from the March 2026 issue of JDD? A systematic review covering reports through March 2025 synthesizes available evidence on nail disorders linked to FGFR inhibitors across multiple tumor types. The authors found that nail adverse events are variably reported across agents, are most often low grade, and are managed with measures such as antiseptic soaks, topical steroids, oral antibiotics, and protective nail care.
Severe events were uncommon and only rarely prompted dose reduction in the series reviewed. The review highlights gaps in our understanding of pathogenesis and the absence of predictive biomarkers, and it emphasizes the potential impact of these toxicities on patient quality of life and treatment adherence.
Click through to the full JDD article to examine the agent specific incidence data, timing and severity of events, and practical management strategies that may inform counseling and multidisciplinary care in your clinic.
Blog write-up assisted by AI
